How to Choose a Menopause Telehealth Provider: An Editorial Buyer's Guide

How to choose menopause telehealth is a question more women are asking as virtual care platforms multiply. Roughly 1.3 million U.S. women enter menopause every year¹, yet only 31.3% of OB-GYN residency programs include a formal menopause curriculum², leaving a meaningful gap between symptom burden and trained clinicians. Telehealth has emerged as a practical answer — offering NAMS-credentialed access, lab-supported prescribing, and asynchronous follow-up. This editorial guide walks through the credentialing, pricing, prescribing, and workflow questions to weigh before subscribing, so the comparison feels concrete rather than marketing-driven.

Key facts at a glance

• About 1.3 million U.S. women reach menopause each year; median symptom duration is 7.4 years per the SWAN study.
• Only ~31% of OB-GYN residencies include formal menopause training²; the NCMP credential helps identify dedicated practitioners.
• Cash-pay initial telehealth consults cluster $99-$295; subscription access $20-$100/month; medications billed separately.
• Seven factors to compare: credentials, state coverage, prescribing scope, lab workflow, insurance model, communication cadence, and price transparency.

What "menopause telehealth" actually means

Menopause telehealth refers to virtual care platforms whose clinicians focus specifically on perimenopause and postmenopause — vasomotor symptoms, genitourinary syndrome of menopause (GSM), sleep, mood, bone health, and sexual function. The 2022 NAMS position statement¹ recognizes hormone therapy as the most effective treatment for moderate-to-severe vasomotor symptoms in appropriate candidates, and the 2023 NAMS non-hormone statement³ recognizes fezolinetant, low-dose paroxetine, SSRIs/SNRIs, gabapentin, and CBT for those who cannot or prefer not to use hormones.

Telehealth scope expanded materially after the 2020 federal public health emergency, with CMS extending several flexibilities and many states maintaining interstate telehealth licensure compacts⁵. What used to require an in-person GYN visit — initial hormone therapy prescription, dose titration, vaginal estrogen renewal — can now be handled by a licensed clinician via video or asynchronous messaging in most states. The remaining question is which provider is the right fit, since the category ranges from solo NCMP-led practices to venture-funded subscription platforms.

The seven factors that actually differentiate providers

1. Clinician credentials

The single most useful credential to look for is NCMP (NAMS Certified Menopause Practitioner), now administered by The Menopause Society. NCMPs pass a competency exam covering hormone therapy risk-benefit, dosing forms, non-hormonal options, bone density, GSM, and sexual function. Only roughly 1,200 active NCMPs practice in the U.S. — a tiny fraction of clinicians who see menopausal women. NCMP status is not legally required to prescribe HRT, but it is a strong signal of dedicated menopause training.

Beyond NCMP, examine each clinician's underlying license (MD, DO, NP, PA, CNM), specialty (gynecology, family medicine, internal medicine, endocrinology), and any post-graduate menopause fellowships or coursework.

2. State licensure

Clinicians must be licensed in the state where the patient is physically located at the time of the visit. Platforms cover state combinations differently; some operate in all 50 states by maintaining a multi-state clinician network, others 30-40 states. The Federation of State Medical Boards tracks interstate telemedicine policies⁸; verify before paying.

3. Prescribing scope

Not every platform prescribes every option. Confirm coverage of: oral estradiol, transdermal estradiol (patch, gel, spray), micronized progesterone, combination products, vaginal estrogen (cream, tablet, ring), low-dose testosterone where clinically appropriate, fezolinetant⁷, SSRI/SNRI options, and gabapentin. ACOG's 2023 menopause guideline³ outlines candidate evaluation across these classes.

4. Lab workflow

Some platforms order baseline labs (FSH, estradiol, lipid panel, TSH, vitamin D, comprehensive metabolic panel) before prescribing; others prescribe based on symptoms alone, consistent with ACOG and NAMS guidance that menopause diagnosis is clinical for women over 45 with characteristic symptoms. Ask whether labs are required, optional, covered by insurance, partnered with Quest/Labcorp, or shipped at-home, and how results are reviewed.

5. Insurance vs cash-pay

Insurance-network providers reduce per-visit cost but may have narrower clinician panels and longer wait times. Cash-pay providers offer faster access but higher out-of-pocket cost. Costs vary widely: cash-pay initial visits commonly $99-$295, subscription access $20-$100/month, generic estradiol $10-$30/month, brand fezolinetant retail approximately $550/month⁷.

6. Communication cadence

Async-first platforms emphasize messaging-based follow-up with response windows usually 24-48 hours — convenient for dose adjustments and side-effect questions. Video-first platforms emphasize scheduled visits — useful for initial intake and complex cases. Most modern platforms blend both, but the dominant mode shapes the experience.

7. Price transparency

A clear monthly cost line item, an itemized medication price, and disclosure of any required ancillary fees (labs, shipping, follow-up visit charges) separate well-run platforms from those that surprise patients on month two.

Treatment options telehealth providers handle

Per the 2022 NAMS position statement¹ and 2023 ACOG guideline³, common options that a menopause telehealth clinician may discuss with a patient include:

• Systemic hormone therapy — estradiol (oral, transdermal) with or without progestogen for women with an intact uterus. NAMS finds the benefit-risk profile favorable for symptomatic women under 60 or within 10 years of menopause onset without contraindications.
• Vaginal estrogen — local low-dose estradiol cream, tablet, or ring for GSM; minimal systemic absorption.
• Fezolinetant (Veozah) — FDA-approved NK3 receptor antagonist for moderate-to-severe vasomotor symptoms⁷; phase 3 SKYLIGHT trials cut symptoms 55-65%.
• Low-dose paroxetine 7.5mg — only SSRI specifically FDA-approved for vasomotor symptoms.
• SNRIs (venlafaxine, desvenlafaxine), gabapentin, oxybutynin — evidence-supported off-label options per NAMS³.
• CBT for menopausal symptoms — strong evidence for symptom bother reduction.

These are editorial summaries of clinical literature, not recommendations. Treatment choice always belongs to a patient and her clinician.

Telehealth provider options to compare

The category includes platforms with different positioning. The most-cited examples in the menopause telehealth space include:

• Midi Health — in-network with major insurers and Medicare in many states; NCMP-trained clinicians; video + async messaging.
• Alloy Women's Health — cash-pay subscription with async-first model; menopause-focused NCMP and OB-GYN clinicians; bundled HRT pricing.
• Evernow — cash-pay async messaging platform; menopause-only focus; subscription includes clinician access and prescription fulfillment.
• Gennev — video-first visits with NAMS-credentialed clinicians; combines clinical care with health coaching and supplements; HSA/FSA accepted.

These are descriptive editorial mentions rather than rankings. Each operates in different state combinations, with different insurance models, and different prescribing scope. Confirm coverage for your state and your specific symptom picture before signing up.

Safety, contraindications, and when to see a doctor

Hormone therapy is not appropriate for every patient. NAMS¹ and ACOG³ identify contraindications including a history of estrogen-sensitive breast cancer, unexplained vaginal bleeding, active liver disease, recent venous thromboembolism, recent stroke or MI, and active or recent endometrial cancer. The Women's Health Initiative long-term mortality analysis⁶ found no significant difference in all-cause mortality between hormone therapy and placebo over 18 years of follow-up — useful context but not a substitute for individualized assessment.

Telehealth is generally well-suited to typical menopause symptom management. In-person evaluation is appropriate for: unexplained postmenopausal bleeding, suspected fracture or significant osteoporosis workup, suspected breast pathology, complex cardiovascular history requiring exam-based risk stratification, and any acute symptoms (chest pain, severe headache with neurologic signs, severe abdominal pain). A patient and a clinician should jointly decide when virtual care is sufficient and when a physical exam is needed.

A good telehealth provider has a clear protocol for escalation — written guidance on when to seek in-person or emergency care.

Cost and insurance considerations

Cost structures fall into four broad models:

• Insurance-billed visits — copay per visit, often $0-$50 depending on plan; some platforms additionally charge a membership fee.
• Cash-pay one-time consults — $99-$295 typical range for an initial 30-60 minute visit.
• Subscription — $20-$100/month for clinician access, usually including messaging and follow-up dose adjustments; medications priced separately.
• Bundled — flat monthly fee including basic generic medications shipped to the patient.

Generic oral estradiol commonly costs $10-$30/month at major pharmacies; transdermal estradiol patches $30-$100/month with insurance; micronized progesterone $20-$60/month. Fezolinetant brand price runs approximately $550/month before insurance⁷; coverage is improving but uneven. HSA and FSA funds typically cover both visit fees and prescription medications. CMS expanded telehealth flexibilities for Medicare beneficiaries⁵, though menopause-specific coverage varies.

A useful price-transparency test: can you find total expected monthly cost (visits + medications + labs) before entering a credit card? If not, ask.

Frequently asked questions

What should I look for when choosing a menopause telehealth provider?

Look for clinician credentials (NAMS Certified Menopause Practitioner status is the gold standard), state licensure in your state, transparent pricing, prescribing scope that covers both hormonal and non-hormonal options, structured lab workflows, and a communication cadence that matches how you want to be cared for (async messaging vs scheduled video).

Is NAMS certification important for menopause telehealth?

NAMS certification (now The Menopause Society's NCMP credential) indicates a clinician passed a competency exam covering hormone therapy, non-hormonal treatment, bone health, and sexual function. It is not legally required, but it is the most widely recognized marker of dedicated menopause training and a reasonable filter when comparing providers.

Does insurance cover menopause telehealth visits?

Coverage varies. Some providers like Midi Health are in-network with major insurers; others (Alloy, Evernow) operate cash-pay. The 2008 Mental Health Parity Act and post-2020 telehealth expansions improved coverage broadly, but menopause-specific telehealth coverage depends on plan, state, and the clinician's network status. Verify before subscribing.

Can a telehealth provider prescribe HRT?

Yes, licensed clinicians (physicians, nurse practitioners, physician assistants) can prescribe systemic estrogen, progestogens, vaginal estrogen, testosterone where appropriate, and non-hormonal options like fezolinetant or low-dose paroxetine via telehealth in states where they are licensed. Scope varies by provider — confirm before signing up.

What's the difference between async messaging and video visits?

Async messaging lets you write to your clinician on your own schedule, typically receiving a response within 24-48 hours; convenient for dose adjustments and questions. Video visits provide real-time conversation, useful for initial intake and complex symptom review. Many menopause telehealth platforms combine both.

How much does menopause telehealth cost out of pocket?

Cash-pay initial consults range $99-$295. Ongoing subscription models commonly run $20-$100/month for clinician access; medications are billed separately. Generic estradiol can be $10-$30/month; brand fezolinetant retail price is approximately $550/month. Always confirm total monthly cost, not just the platform fee.

Sources

1. The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/35797481/
2. Kling JM, MacLaughlin KL, Schnatz PF, et al. Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents: A Cross-Sectional Survey. Mayo Clin Proc. 2019;94(2):242-253. https://pubmed.ncbi.nlm.nih.gov/30527866/
3. ACOG Clinical Practice Guideline No. 6: Management of Menopausal Symptoms. Obstet Gynecol. 2023;142(3):720-742. https://www.acog.org/clinical/clinical-guidance/clinical-practice-guideline/articles/2023/09/management-of-menopausal-symptoms
4. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. https://pubmed.ncbi.nlm.nih.gov/37252752/
5. Centers for Medicare & Medicaid Services. Telehealth Services Coverage Expansion and Permanent Changes. CMS.gov Fact Sheet. 2023. https://www.cms.gov/newsroom/fact-sheets/telehealth
6. Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938. https://pubmed.ncbi.nlm.nih.gov/28898378/
7. US Food and Drug Administration. VEOZAH (fezolinetant) Prescribing Information. May 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216578s000lbl.pdf
8. Federation of State Medical Boards. Telehealth Policies by State. FSMB Report. 2024. https://www.fsmb.org/siteassets/advocacy/key-issues/telemedicine_policies_by_state.pdf

Related brands & guides

Updated May 30, 2026. Reviewed by Jane Smith, MD.